retatrutide triple agonist obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Original Article: Triple–Hormone-Receptor Agonist Retatrutide

This price tag often forces patients to choose between their health goals and their financial stability, a decision nobody should have to make

Figure 1 shows the average likelihood rating for each food system player across participants with and without GLP-1 medication experience

Regarding gonadal effects, treatment with GLP1/E, GLP1/GIP, and metformin did not alter ovarian or uterus weights, nor did they change circulating LH levels in this hyperandrogenic model of PCOS (Suppl

However, as with injectable GLP-1s, cost may be a consideration in determining access to the Wegovy pill, particularly since many insurance plans dont cover obesity medications, Dushay says

Finley said her physician told her a prior authorization was on file, but when she tried to refill her prescription, the pharmacist told her Zepbound was denied